LU90842I2 - Mabcampath-alemtuzumab et ses d-riv-s pharmaceutiquement acceptables - Google Patents

Mabcampath-alemtuzumab et ses d-riv-s pharmaceutiquement acceptables

Info

Publication number
LU90842I2
LU90842I2 LU90842C LU90842C LU90842I2 LU 90842 I2 LU90842 I2 LU 90842I2 LU 90842 C LU90842 C LU 90842C LU 90842 C LU90842 C LU 90842C LU 90842 I2 LU90842 I2 LU 90842I2
Authority
LU
Luxembourg
Prior art keywords
mabcampath
alemtuzumab
pharmaceutically acceptable
acceptable derivatives
framework regions
Prior art date
Application number
LU90842C
Other languages
English (en)
Original Assignee
Btg Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB888803228A external-priority patent/GB8803228D0/en
Priority claimed from GB888804464A external-priority patent/GB8804464D0/en
Application filed by Btg Int Ltd filed Critical Btg Int Ltd
Publication of LU90842I2 publication Critical patent/LU90842I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
LU90842C 1988-02-12 2001-09-26 Mabcampath-alemtuzumab et ses d-riv-s pharmaceutiquement acceptables LU90842I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB888803228A GB8803228D0 (en) 1988-02-12 1988-02-12 Improvements in/relating to antibodies
GB888804464A GB8804464D0 (en) 1988-02-25 1988-02-25 Improvements in/relating to antibodies

Publications (1)

Publication Number Publication Date
LU90842I2 true LU90842I2 (fr) 2001-11-26

Family

ID=26293475

Family Applications (1)

Application Number Title Priority Date Filing Date
LU90842C LU90842I2 (fr) 1988-02-12 2001-09-26 Mabcampath-alemtuzumab et ses d-riv-s pharmaceutiquement acceptables

Country Status (13)

Country Link
EP (1) EP0328404B1 (fr)
JP (2) JP3121823B2 (fr)
AT (1) ATE95068T1 (fr)
AU (1) AU618989B2 (fr)
CA (1) CA1339198C (fr)
DE (2) DE68909441T2 (fr)
DK (1) DK174854B1 (fr)
ES (1) ES2059719T3 (fr)
GB (1) GB2216126B (fr)
LU (1) LU90842I2 (fr)
NL (1) NL300067I1 (fr)
NZ (1) NZ227968A (fr)
WO (1) WO1989007452A1 (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
JPH05500608A (ja) * 1989-09-19 1993-02-12 セントカー・インコーポレーテツド ヒトモノクローナル抗体の産生を改良する方法
US6750325B1 (en) 1989-12-21 2004-06-15 Celltech R&D Limited CD3 specific recombinant antibody
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9020282D0 (en) 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
GB9022547D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Purified immunoglobulin
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
GB9022543D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Antibody production
KR100240308B1 (ko) * 1991-03-06 2000-01-15 플레믹 크리스티안 인간화된단클론성항체및혼성단클론성항체
GB9105245D0 (en) * 1991-03-12 1991-04-24 Lynxvale Ltd Binding molecules
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
GB9108056D0 (en) * 1991-04-16 1991-06-05 Hale Geoffrey Synthetic antigen
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
WO1994004679A1 (fr) * 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
EP0940468A1 (fr) 1991-06-14 1999-09-08 Genentech, Inc. Domaine variable d'un anticorps humanisé
GB9114468D0 (en) * 1991-07-04 1991-08-21 Wellcome Found Antibody production
GB9115364D0 (en) * 1991-07-16 1991-08-28 Wellcome Found Antibody
US6764681B2 (en) 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
ES2125977T3 (es) * 1991-10-15 1999-03-16 Btg Int Ltd Cdw52-anticuerpo especifico para el tratamiento de la inflamacion de las articulaciones mediada por celulas t.
GB9125768D0 (en) * 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
JPH05244982A (ja) * 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
DE4225853A1 (de) * 1992-08-05 1994-02-10 Behringwerke Ag Granulozytenbindende Antikörperfragmente, ihre Herstellung und Verwendung
JP3415840B2 (ja) * 1992-11-28 2003-06-09 財団法人化学及血清療法研究所 外来蛋白質の産生方法
GB9325182D0 (en) * 1993-12-08 1994-02-09 T Cell Sciences Inc Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
US6010861A (en) * 1994-08-03 2000-01-04 Dgi Biotechnologies, Llc Target specific screens and their use for discovering small organic molecular pharmacophores
GB9603507D0 (en) * 1996-02-20 1996-04-17 Isis Innovation Antibody variants
EP1378525A3 (fr) 1996-06-07 2004-01-14 Neorx Corporation Anticorps humanisés qui se lient à l'antigène relié par l'anticorp NR-LU-13 et leur utilisation dans des méthodes de ciblage
US7858095B2 (en) 2001-07-24 2010-12-28 Astellas Us Llc Method for treating or preventing sclerotic disorders using CD-2 binding agents
US20060228351A1 (en) * 2003-03-31 2006-10-12 Junichi Masuyama Method of inducing differentiation and proliferating regulatory t cell by anti-cd52 antibody and medicinal composition therefor
RU2386638C2 (ru) 2004-03-31 2010-04-20 Дженентек, Инк. Гуманизированные анти-тфр-бета-антитела
CA2565259A1 (fr) 2004-05-07 2005-12-08 Astellas Us Llc Polypeptide lfa-3 soluble destine a traiter de troubles viraux
MY160126A (en) 2009-05-13 2017-02-28 Genzyme Corp Anti-human cd52 immunoglobulins
GB201109238D0 (en) * 2011-06-01 2011-07-13 Antitope Ltd Antibodies
US20140359902A1 (en) 2011-12-16 2014-12-04 Synthon Biopharmaceuticals B.V. EXPRESSION OF SECRETORY IgA ANTIBODIES IN DUCKWEED
KR20190133005A (ko) 2017-03-24 2019-11-29 젠야쿠코교가부시키가이샤 항 IgM/B 세포 표면 항원 이중 특이성 항체

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product

Also Published As

Publication number Publication date
DK502189A (da) 1989-10-12
AU3062689A (en) 1989-09-06
DK174854B1 (da) 2003-12-22
GB2216126B (en) 1992-06-03
GB8902978D0 (en) 1989-03-30
NL300067I1 (nl) 2001-12-01
GB2216126A (en) 1989-10-04
EP0328404A1 (fr) 1989-08-16
DK502189D0 (da) 1989-10-10
WO1989007452A1 (fr) 1989-08-24
CA1339198C (fr) 1997-08-05
DE68909441T2 (de) 1994-02-10
JPH02503514A (ja) 1990-10-25
JPH11228600A (ja) 1999-08-24
EP0328404B1 (fr) 1993-09-29
AU618989B2 (en) 1992-01-16
DE10199051I1 (de) 2002-01-10
DE68909441D1 (de) 1993-11-04
JP3121823B2 (ja) 2001-01-09
ATE95068T1 (de) 1993-10-15
DE10199051I2 (de) 2005-05-04
ES2059719T3 (es) 1994-11-16
NZ227968A (en) 1992-01-29

Similar Documents

Publication Publication Date Title
LU90842I2 (fr) Mabcampath-alemtuzumab et ses d-riv-s pharmaceutiquement acceptables
DE68918497D1 (de) Monoklonale Mäuseantikörper gegen HIV-IP24 und ihre Verwendung in Diagnostika.
FI925098A7 (fi) Ihmisen papilloomavirusten 1,5,6,8,11,16,18,31,33 ja 56 synteettisiä p eptidejä, jotka ovat käyttökelpoisia immunoanalyysissä diagnostisiin t arkoituksiin
FR2691602B1 (fr) Accélérateur linéaire de protons à focalisation améliorée et impédance shunt élevée.
DE69616522D1 (de) Windel mit mehreren aufrechten beinklappen
DE68914029D1 (de) Arylmethylenderivate von Thiazolidinonen, Imidazolidinonen und Oxazolidininonen, nützlich als antiallergische Wirkstoffe und antiinflammatorische Wirkstoffe.
DE69116398D1 (de) Basenbeständige Fluorelastomere mit verbesserter Verarbeitbarkeit und Härtbarkeit
EP0593290A3 (fr) Proteine antigènique du noyau du virus de l'hépatite C, et méthode diagnostiquée et nécessaire.
IT8967343A0 (it) Anticorpo umano monoclonale ed ibridoma che produce il medesimo
KR910002005A (ko) 바이폴라트랜지스터와 그 제조방법
DE69100679D1 (de) Vergasende Verbrennungsmethode und vergasende Energieerzeugungsmethode.
NO905251D0 (no) Fremgangsmaate for serie - fremstilling av ammunisjonslegemer samt ammunisjonslegemer fremstilt i henhold til fremgangsmaaten.
DE68908880D1 (de) Äthanolbrennstoff und dessen verwendung als dieselbrennstoff.
DE69129582D1 (de) Antikörper gegen menschlichen plasmin-alpha 2-plasmininhibitor-komplex, hybridoma und immunoassay
DE69024871D1 (de) Monoklonaler Antikörper gegen menschliches BCDF und Immuntestverfahren unter dessen Verwendung
ATE109834T1 (de) Monoklonaler antikörper spezifisch gegen humane pankreas-phospholipase-a2.
DE69013372D1 (de) Ori-gehemmte und niederschlagsbeständige Motorkraftstoffzusammensetzung.
DE68924495D1 (de) Halbleiter-Bauelement mit verbesserter Gate-Kapazität und dessen Herstellungsverfahren.
DE68912772D1 (de) Monoklonaler antikörper gegen entero-viren.
FI902364A0 (fi) Anordning foer istaondsaettande av underbacken i en hoppbacke.
ATE148163T1 (de) Monoklonale antikörper gegen leptosphaeria
RU1808414C (ru) Устройство дл сортировки и перемещени сыпучих материалов
MX9100291A (es) Nuevos derivados de la 6-metil 19-nor progesterona,substituidos en 3 y su procedimiento de obtencion
SU640010A1 (ru) Винтовой замок
Shapiro Another cause of tennis elbow